Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.

Myers SA, Selim AA, McDaniel MA, Hall R, Zhang Y, Bartlett JA, True AL.

Antivir Ther. 2006;11(7):935-9.

PMID:
17302257
2.

Selective increase in serum IgE following enfuvirtide administration in HIV-1 infected multidrug resistant patients.

Hasson H, Biswas P, Galli L, Burastero SE, Danise A, Bigoloni A, Carini E, Locatelli M, Vecchi A, Lazzarin A, Castagna A.

New Microbiol. 2006 Oct;29(4):223-30.

PMID:
17201088
4.

A randomized study to evaluate injection site reactions using three different enfuvirtide delivery mechanisms (the OPTIONS study).

Boyd MA, Truman M, Hales G, Anderson J, Dwyer DE, Carr A.

Antivir Ther. 2008;13(3):449-53.

PMID:
18572758
5.

Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.

Wright D, Rodriguez A, Godofsky E, Walmsley S, Labriola-Tompkins E, Donatacci L, Shikhman A, Tucker E, Chiu YY, Chung J, Rowell L, Demasi R, Graham N, Salgo M.

HIV Clin Trials. 2008 Mar-Apr;9(2):73-82. doi: 10.1310/hct0902-73.

PMID:
18474492
6.

T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.

Lalezari JP, Bellos NC, Sathasivam K, Richmond GJ, Cohen CJ, Myers RA Jr, Henry DH, Raskino C, Melby T, Murchison H, Zhang Y, Spence R, Greenberg ML, Demasi RA, Miralles GD; T1249-102 Study Group.

J Infect Dis. 2005 Apr 1;191(7):1155-63. Epub 2005 Feb 22.

PMID:
15747252
7.

TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.

Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP.

AIDS Patient Care STDS. 2007 Aug;21(8):533-43.

PMID:
17711378
8.

Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure.

Cossarini F, Galli L, Sagnelli C, Gianotti N, Hasson H, Clementi M, Soria A, Salpietro S, Lazzarin A, Castagna A.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):179-84. doi: 10.1097/QAI.0b013e3181a56f46.

PMID:
19352200
9.

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.

Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21.

PMID:
16280695
10.

Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).

Harris M, Joy R, Larsen G, Valyi M, Walker E, Frick LW, Palmatier RM, Wring SA, Montaner JS.

AIDS. 2006 Mar 21;20(5):719-23.

PMID:
16514302
11.

Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.

Belperio PS, Mole LA, Halloran J, Boothroyd DB, Thomas IC, Backus LI.

Ann Pharmacother. 2008 Nov;42(11):1573-80. doi: 10.1345/aph.1L265. Epub 2008 Oct 21.

PMID:
18940919
12.

Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.

Clotet B, Raffi F, Cooper D, Delfraissy JF, Lazzarin A, Moyle G, Rockstroh J, Soriano V, Schapiro J.

AIDS. 2004 May 21;18(8):1137-46. Review.

PMID:
15166529
13.

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.

Sista PR, Melby T, Davison D, Jin L, Mosier S, Mink M, Nelson EL, DeMasi R, Cammack N, Salgo MP, Matthews TJ, Greenberg ML.

AIDS. 2004 Sep 3;18(13):1787-94.

PMID:
15316339
14.

Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.

Dwyer DE, Workman C, Hales G, Amin J, Cooper D, Miller J; Alliance Study Group.

Antivir Ther. 2006;11(4):409-19.

PMID:
16856614
15.

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.

Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L.

Scand J Infect Dis. 2011 May;43(5):373-9. doi: 10.3109/00365548.2011.552520. Epub 2011 Feb 22.

PMID:
21341978
16.

Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.

Cervia JS, Smith MA.

Clin Infect Dis. 2003 Oct 15;37(8):1102-6. Epub 2003 Sep 10. Review.

PMID:
14523775
17.

Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.

Lalezari JP, Patel IH, Zhang X, Dorr A, Hawker N, Siddique Z, Kolis SJ, Kinchelow T.

J Clin Virol. 2003 Oct;28(2):217-22.

PMID:
12957192
18.

Virologic and immunologic impact and durability of enfuvirtide-based antiretroviral therapy in HIV-infected treatment-experienced patients in a clinical setting.

Loutfy MR, Antoniou T, Shen S, Diong C, Vlaicu M, Halpenny R, Kovacs C, Fletcher D, Raboud JM.

HIV Clin Trials. 2007 Jan-Feb;8(1):36-44.

PMID:
17434847
19.

An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: the Biojector 2000 Open-label Safety Study (BOSS).

Lalezari JP, Saag M, Walworth C, Larson P.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):805-13. doi: 10.1089/aid.2007.0251.

PMID:
18507525
20.

Enfuvirtide and cutaneous injection-site reactions.

Mirza RA, Turiansky GW.

J Drugs Dermatol. 2012 Oct;11(10):e35-8.

PMID:
23134996

Supplemental Content

Support Center